公开(公告)号：US09822150B2

公开(公告)日：2017-11-21

申请号：US14470922

申请日：2014-08-27

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC: A61K39/00 ,  C07K14/22 ,  A61K39/095 ,  A61K39/12 ,  A61K39/39 ,  C12N7/00 ,  A61K39/13 ,  A61K39/295

CPC classification number: C07K14/22 ,  A61K39/0016 ,  A61K39/095 ,  A61K39/12 ,  A61K39/13 ,  A61K39/295 ,  A61K39/39 ,  A61K2039/5252 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/20034 ,  C12N2770/32634 ,  Y02A50/466

Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US09724402B2

公开(公告)日：2017-08-08

申请号：US15237005

申请日：2016-08-15

Applicant: PFIZER INC.

Inventor： Annaliesa Sybil Anderson ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark E. Ruppen

IPC: A61K39/095 ,  C07K14/22 ,  C07K16/12 ,  A61K39/00

CPC classification number: A61K39/095 ,  A61K2039/55577 ,  A61K2039/6018 ,  C07K14/22 ,  C07K16/1217

Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71 in another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

公开(公告)号：US11952597B2

公开(公告)日：2024-04-09

申请号：US16922952

申请日：2020-07-07

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10 ,  C07K14/33 ,  C12N1/20

CPC classification number: C12N9/1051 ,  C07K14/33 ,  C12N1/20

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

公开(公告)号：US20240000912A1

公开(公告)日：2024-01-04

申请号：US18034239

申请日：2021-11-01

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Seema Shridhar Gangolli ,  Kathrin Ute Jansen ,  Avvari Krishna Prasad ,  Michael William Pride ,  Ingrid Lea Scully ,  Wendy Jo Watson

IPC: A61K39/09 ,  A61P31/04

CPC classification number: A61K39/092 ,  A61P31/04 ,  A61K2039/70

Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 15, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.

公开(公告)号：US20230233671A1

公开(公告)日：2023-07-27

申请号：US18045967

申请日：2022-10-12

Applicant: Pfizer Inc.

Inventor： Eric Matthew Bennett ,  Fernando Martin Diaz ,  Philip Ralph Dormitzer ,  Kathrin Ute Jansen ,  Raquel Munoz-Moreno ,  Alicia Solorzano Quijano

IPC: A61K39/25 ,  A61K47/69 ,  A61K47/10 ,  A61K47/28 ,  A61P37/04

CPC classification number: A61K39/25 ,  A61K47/6929 ,  A61K47/10 ,  A61K47/28 ,  A61P37/04

Abstract: The present disclosure relates to RNA molecules encoding a varicella zoster virus (VZV). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment or prevention of herpes zoster or shingles.

公开(公告)号：US20210393764A1

公开(公告)日：2021-12-23

申请号：US17463691

申请日：2021-09-01

Applicant: Pfizer Inc.

Inventor： David Cooper ,  Kathrin Ute Jansen ,  Michael William Pride

IPC: A61K39/09 ,  A61K39/385

Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

公开(公告)号：US11160855B2

公开(公告)日：2021-11-02

申请号：US15286696

申请日：2016-10-06

Applicant: Pfizer Inc.

Inventor： Emilio Anthony Emini ,  Wendy Jo Watson ,  Avvari Krishna Prasad ,  Mingming Han ,  Jin-Hwan Kim ,  Jianxin Gu ,  Yu-ying Yang ,  Rajesh Kumar Kainthan ,  David Cooper ,  Michael William Pride ,  Kathrin Ute Jansen

IPC: A61K39/09 ,  A61K47/64 ,  A61K39/00

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

公开(公告)号：US20210024903A1

公开(公告)日：2021-01-28

申请号：US16922952

申请日：2020-07-07

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10 ,  C07K14/33 ,  C12N1/20

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

公开(公告)号：US10899802B2

公开(公告)日：2021-01-26

申请号：US15728610

申请日：2017-10-10

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC: C07K14/22 ,  A61K39/00 ,  C12N7/00 ,  A61K39/13 ,  A61K39/295 ,  A61K39/095 ,  A61K39/12 ,  A61K39/39

Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US10550159B2

公开(公告)日：2020-02-04

申请号：US16208347

申请日：2018-12-03

Applicant: PFIZER INC.

Inventor： Annaliesa Sybil Anderson ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark E. Ruppen

IPC: A61K39/095 ,  C07K14/22

Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.